Skip to content

Cibenzoline

CARDIOVASCULAR SYSTEM

Also known as: (+/-)-Cibenzoline, (RS)-Cibenzoline, cibenzoline succinate, cifenline, cifenline succinate

YEAR INTRODUCED approvedATC C01BG07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cibenzoline is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1978. DrugCentral lists 3 molecular targets, including KCNH2, HCN4 and KCNJ11.

  • Molecular targets: KCNH2, HCN4 and KCNJ11 (3 listed in DrugCentral).
  • ATC code: C01BG07 (Other antiarrhythmics, class I and III).
  • Molecular formula: C18H18N2; molecular weight 262.36 g/mol.

Mechanism & targets

Molecular targets (3)

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1978-01-01YEAR INTRODUCED——

ATC classification

ATC codeTherapeutic hierarchy
C01BG07CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Other antiarrhythmics, class I and III

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Cibenzoline is on its molecule page.

Molecular formulaC18H18N2
Molecular weight262.36 g/mol
CAS number53267-01-9
InChIKeyIPOBOOXFSRWSHL-UHFFFAOYSA-N
PubChem CID2747
C1C(C2=NCCN2)C1(C1=CC=CC=C1)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

How does Cibenzoline work?

Its molecular targets in DrugCentral include KCNH2, HCN4 and KCNJ11.

When was Cibenzoline first approved?

Cibenzoline was first approved by the YEAR INTRODUCED in 1978.

What is the chemical formula of Cibenzoline?

Cibenzoline has the molecular formula C18H18N2 and a molecular weight of 262.36 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval1978-01-01
AgencyYEAR INTRODUCED
Targets3
Indications0
FormulaC18H18N2
DrugCentral ID630
Interactive profile